¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"cell wall antigen"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 10
  • ¿µ¹®
    ÇѱÛ
  • clear cell acanthoma
    Åõ¸í¼¼Æ÷°¡½Ã¼¼Æ÷Á¾, Åõ¸í¼¼Æ÷±Ø¼¼Æ÷Á¾
  • clear cell adenocarcinoma
    Åõ¸í¼¼Æ÷»ù¾ÏÁ¾, Åõ¸í¼¼Æ÷¼±¾ÏÁ¾
  • clear cell carcinoma
    Åõ¸í¼¼Æ÷¾ÏÁ¾
  • clear cell hidradenoma
    Åõ¸í¼¼Æ÷¶¡»ùÁ¾
  • clear cell sarcoma
    Åõ¸í¼¼Æ÷À°Á¾
  • columnar cell
    ¿øÁÖ¼¼Æ÷
  • committed cell
    ¾ô¸Ç¼¼Æ÷, ¼öÀÓ¼¼Æ÷
  • complex cell
    º¹ÇÕ¼¼Æ÷
  • cone cell
    ¿ø»Ô¼¼Æ÷
  • cone cell layer
    ¿ø»Ô¼¼Æ÷Ãþ, ¿øÃß¼¼Æ÷Ãþ
  • connective tissue cell
    °áÇÕÁ¶Á÷¼¼Æ÷
  • continuous cell line
    ¹«ÇÑÁõ½Ä¼¼Æ÷ÁÖ, ¿¬¼Ó°è´ë¼¼Æ÷ÁÖ
  • contractile fiber cell
    ¼öÃ༶À¯¼¼Æ÷
  • cover cell
    µ¤°³¼¼Æ÷
  • crenated cell
    Åé´ÏÀûÇ÷±¸
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 10
  • ¿µ¹®
    ÇѱÛ
  • basal cell nevus syndrome
    ¹Ù´Ú¼¼Æ÷¸ð¹ÝÁõÈıº, ±âÀú¼¼Æ÷¸ð¹ÝÁõÈıº
  • basket cell
    ¹Ù±¸´Ï¼¼Æ÷
  • basophilic cell
    È£¿°±â¼¼Æ÷
  • basosquamous cell carcinoma
    ¹Ù´ÚÆíÆò¼¼Æ÷¾ÏÁ¾, ±âÀúÆíÆò¼¼Æ÷¾ÏÁ¾
  • beta cell
    º£Å¸¼¼Æ÷
  • bipolar cell
    µÎ±Ø¼¼Æ÷
  • blood cell
    Ç÷¾×¼¼Æ÷, Ç÷±¸
  • blood cell separator
    Ç÷±¸ºÐ¸®±â
  • bone marrow-derived cell
    °ñ¼öÀ¯·¡¼¼Æ÷
  • border cell
    °æ°è¼¼Æ÷, ¼Ó°æ°è¼¼Æ÷
  • bristle cell
    ¾ï¼¾Åм¼Æ÷, °­¸ð¼¼Æ÷
  • burr cell
    ¹«µòÅ鳯ÀûÇ÷±¸
  • cell bank
    ¼¼Æ÷ÀºÇà
  • nerve cell body
    ½Å°æ¼¼Æ÷ü
  • cell
    ¼¼Æ÷
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 10
  • ¿µ¹®
    ÇѱÛ
  • antigen recognition
    Ç׿øÀÎÁö
  • antigen recognition site
    Ç׿ø½Äº°ºÎ.
  • antigen, Rh
    RhÇ׿ø
  • antigen, Thy-1
    Thy-1Ç׿ø
  • antigen, Vi
    ViÇ׿ø
  • antigen, capsular
    Çù¸·Ç׿ø
  • antigen, carcinoembryonic
    ¾ÏžÆÇ׿ø
  • antigen, colonization factor
    Áý¶ôÇü¼ºÀÎÀÚÇ׿ø, ¼¼Æ÷±ºÇü¼ºÀÎÀÚÇ׿ø
  • antigen, complete
    ¿ÏÀüÇ׿ø
  • antigen, conjugated
    °áÇÕÇ׿ø
  • antigen, cross-reacting
    ±³Â÷¹ÝÀÀÇ׿ø
  • antigen, fetal
    žÆÇ׿ø
  • antigen, fimbrial
    ¼¶¸ðÇ׿ø
  • antigen, flagellar
    Æí¸ðÇ׿ø
  • antigen, hepatitis B core
    BÇü °£¿°¹ÙÀÌ·¯½º ÇÙ½ÉÇ׿ø
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 10
  • ¿µ¹®
    ÇѱÛ
  • antigen diffusion constant
    Ç׿øÈ®»ê»ó¼ö(ù÷ê«üªß¤ßÈâ¦).
  • antigen drift
    Ç׿ø¼Òº¯ÀÌ.
  • antigen excess
    Ç׿ø°ú´Ù(ù÷ê«Î¦Òý).
  • antigen excess zone
    Ç׿ø°úÀ×´ë.
  • antigen excess zone
    Ç׿ø°úÀ×´ë.
  • antigen excess zone
    Ç׿ø°úÀ×´ë.
  • antigen mimicry
    Ç׿øÀ¯»ç¼º.
  • antigen modification
    Ç׿øº¯Çü.
  • antigen presentation
    Ç׿øÁ¦°ø, Ç׿øÀü´Þ, Ç׿øÁ¦½Ã
  • antigen presenting cells
    Ç׿ø Àü´Þ ¼¼Æ÷
  • antigen receptor
    Ç׿ø¼ö¿ëü.
  • antigen recognition
    Ç׿øÀÎÁö
  • antigen recognition site
    Ç׿ø½Äº°ºÎ.
  • antigen tolerance
    Ç׿ø°ü¿ë.
  • antigen unit
    Ç׿ø´ÜÀ§.
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 10
  • ¿µ¹®
    ÇѱÛ
  • Glial cell body
    ¾Æ±³¼¼Æ÷ü
    [¿¾ ¿ë¾î] ±³¼¼Æ÷ü
  • Ameboid cell
    ¾Æ¸Þ¹Ù¸ð¾ç¼¼Æ÷
    [¿¾ ¿ë¾î] ¾Æ¸Þ¹Ù¾ç¼¼Æ÷
  • Dark cell
    ¾îµÎ¿î¼¼Æ÷
    [¿¾ ¿ë¾î] ¾Ï¼¼Æ÷
  • Dark cell
    ¾îµÎ¿î¼¼Æ÷
    [¿¾ ¿ë¾î] ¾ÏÁÖ¼¼Æ÷
  • Trophoblastic giant cell
    ¿µ¾ç¸·°Å´ë¼¼Æ÷
    [¿¾ ¿ë¾î] °Å´ë¿µ¾ç¸·¼¼Æ÷
  • Primordial germ cell
    ¿ø½ÃÁ¾ÀÚ¼¼Æ÷
    [¿¾ ¿ë¾î] ¿ø±âÁ¾(¹è)¼¼Æ÷
  • Primordial germ cell
    ¿ø½ÃÁ¾ÀÚ¼¼Æ÷
    [¿¾ ¿ë¾î] ¿ø±âÁ¾¼¼Æ÷
  • Primordial germ cell
    ¿ø½ÃÁ¾ÀÚ¼¼Æ÷
    [¿¾ ¿ë¾î] ¿ø½ÃÁ¾ÀÚ¼¼Æ÷
  • Columnar ependymal cell
    ¿øÁÖ³ú½Ç¸·¼¼Æ÷
    [¿¾ ¿ë¾î] ¿øÁÖ»óÀǼ¼Æ÷
  • Columnar epithelial cell
    ¿øÁÖ»óÇǼ¼Æ÷
    [¿¾ ¿ë¾î] ¿øÁÖ»óÇǼ¼Æ÷
  • Columnar cell
    ¿øÁÖ¼¼Æ÷
    [¿¾ ¿ë¾î] ¿øÁÖ¼¼Æ÷
  • Type II hair cell
    ¿øÁÖÅм¼Æ÷
    [¿¾ ¿ë¾î] ÀüÆÄ¿¬Á¢¼¼Æ÷
  • Secretory cell of pyloric gland
    À§³¯¹®»ù¼¼Æ÷
    [¿¾ ¿ë¾î] À¯¹®¼±¼¼Æ÷
  • Secretory cell of cardiac gland
    À§µé¹®»ù¼¼Æ÷
    [¿¾ ¿ë¾î] ºÐ¹®¼±¼¼Æ÷
  • Gastrointestinal endocrine cell
    À§Ã¢ÀÚ³»ºÐºñ¼¼Æ÷
    [¿¾ ¿ë¾î] À§Ã¢ÀÚ³»ºÐºñ¼¼Æ÷
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 10
  • ¿µ¹®
    ÇѱÛ
  • sickle cell anemia
    ³´¼¼Æ÷(á¬øà)ºóÇ÷(Þ¸úì)
  • sickle cell disease
    ³´¼¼Æ÷(á¬øà)Áúȯ(òðü´)
  • sickle cell hemoglobin
    ³´¼¼Æ÷(á¬øà)È÷¸ð±Û·Îºó
  • sickle cell trait
    ³´¼¼Æ÷(á¬øà)¼ºÇâ(àõú¾)
  • single-cell protein
    ´Ü¼¼Æ÷ ´Ü¹éÁú(Ó¤á¬øàÓ±ÛÜòõ)
  • somatic cell
    ü¼¼Æ÷(ô÷á¬øà)
  • somatic cell genetic engineering
    ü¼¼Æ÷ À¯Àü°øÇÐ(ô÷á¬øàë¶îîÍïùÊ)
  • somatic cell hybrid
    ü¼¼Æ÷(ô÷á¬øà) Æ¢±â
  • suppressor T cell
    ¾ï¾Ð(åääâ) T ¼¼Æ÷(á¬øà)
  • synthetic boundary cell
    ÇÕ¼º °æ°è½Ç (ùêà÷ÌÑÍ£ãø)
  • target cell
    Ç¥Àû¼¼Æ÷ (øöîÜá¬øà)
  • T cell
    T ¼¼Æ÷(á¬øà)
  • T cell growth factor
    T ¼¼Æ÷¼ºÀåÀÎÀÚ (á¬øàà÷íþì×í­)
  • T cell helper
    T ¼¼Æ÷(á¬øà)µµ¿òÀÌ
  • T cell line
    T ¼¼Æ÷ÁÖ(á¬øàñ»)
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 10
TCE T-cell enriched; tetrachlorodiphenyl ethane; trichloroethylene T-cell thymus-derived cell
TCR T-cell reactivity; T-cell receptor; T-cell rosette; thalamocortical relay; total cytoplasmic ribosom...
WBC well baby care/clinic; white blood cell; white blood cell count; whole blood cell count
WC ward clerk; water closet; Weber-Christian [syndrome]; wheel chair; white cell; white cell casts; whi...
GBP scan Gated Blood Pool (cardiac) scan
  = GBPS
  1. LV ±â´É ÃøÁ¤
  2. ...
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 10
SCC Ag Squamous cell carcinoma antigen
SCC-Ag Squamous cell carcinoma-related antigen
TCR T Cell Antigen Receptor
TCR T cell antigen receptor complex
TCR T cell receptor for antigen
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 10
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • benign giant cell tumor
    ¾ç¼º °Å´ë¼¼Æ÷ Á¾¾ç
    1. °ñÀÇ ¾ç¼º °Å´ë¼¼Æ÷Á¾. °ñÀÇ ¾ç¼º Á¾¾çÀÇ Çϳª·Î ³ë¾àÀÚ¿¡°Ô ¸¹À¸¸ç ¹ß»ý ºÎÀ§´Â Àå°ü°ñÀÇ °ñ´Ü¿¡ ¸¹ÀÌ ³ªÅ¸³­´Ù. Á¶Á÷ÇÐÀûÀ¸·Î ¿øÇü, ¹æÃßÇüÀÌ ÀÖ´Ù. ¼¼Æ÷ »çÀÌ¿¡ ÆÄ°ñ¼¼Æ÷¿Í À¯»çÇÑ °Å´ë¼¼Æ÷°¡ È¥ÀçÇÑ´Ù. 2. °ÇÃÊÀÇ ¾ç¼º °Å´ë¼¼Æ÷Á¾. º»·¡ Á¾¾çÀÌ ¾Æ´Ï¸ç, °áÁ¤¼º °ÇÃÊ¿°À» °¡¸®Å°¸ç °ÇÃÊÀÇ ¼¶À¯¼º Á¶Á÷±¸Á¾¿¡ Æ÷ÇԵȴÙ.
  • beta cell tumor
    º£Å¸ ¼¼Æ÷Á¾
  • beta-cell tumor
    º£Å¸ ¼¼Æ÷ Á¾¾ç
    µµ¼¼Æ÷ Á¾¾ç Áß °¡Àå ÈçÇÑ Áúº´À¸·Î Àν¶¸° °ú´Ù ºÐºñ°¡ ÀϾ´Ù.
  • bipolar cell
    µÎ ±Ù ½Å°æ¼¼Æ÷, ½Ö±Ø ¼¼Æ÷
    µÎ °³ÀÇ µ¹±â¸¦ °¡Áø ½Å°æ¼¼Æ÷.
  • blood cell counter
    Ç÷±¸ °è¼ö±â
  • bone cell
    °ñ ¼¼Æ÷
    °ñÁ¶Á÷ÀÇ ±âº» ¼¼Æ÷. °ñ Á¶Á÷¿¡´Â µüµüÇÑ °ñ ±âÁú¾È¿¡ °ñ¼Ò°­À̶ó°í ÇÏ´Â Æ´ÀÌ ±ºµ¥±ºµ¥ ÀÖ°í, ±× ¼Ó¿¡ 1°³¾¿ÀÇ °ñ ¼¼Æ÷°¡ µé¾î ÀÖ´Ù. °ñ ¼¼Æ÷ÀÇ ÇüÅ´ °ñ¼Ò°­°ú ÀÏÄ¡ÇÏ¿© ÆíÆòÇÑ Å¸¿øÇüÀ¸·Î, ±æÀÌ´Â 15¡­27 ¥ìmÀÌ´Ù. °ñ ¼¼Æ÷´Â ´Ù¼öÀÇ °¡´Â ¿øÇüÁú µ¹±â°¡ À־, À̰ÍÀÌ ±âÁú ³»ÀÇ °ñ ¼¼°üÀ» ÅëÇÏ¿© °¡±îÀÌ ÀÖ´Â °ñ ¼¼Æ÷ÀÇ µ¹±â¿Í ÇÕÄ£´Ù. °ñ ¼¼Æ÷´Â º»·¡ °áÇÕÁ¶Á÷ÀÇ ¼¶À¯¾Æ¼¼Æ÷¿¡¼­ Çü¼ºµÇ´Â °ÍÀ¸·Î, ¸ÕÀú °ñ¾Æ¼¼Æ÷°¡ µÇ¾î, À̰ÍÀÌ ±âÁúÀ» ¸¸µé°í ÀÚ½ÅÀº ±× ±âÁú ¼Ó¿¡ µé¾î°¡ °ñ¼¼Æ÷·Î µÈ´Ù. À̰ÍÀº °ñ Á¶Á÷ÀÇ Á¦Á¶ÀÚÀ̸ç, ¼¼Æ÷ÁúÀº ¹Ì·®ÀÇ ¹ÌÅäÄܵ帮¾Æ¸¦ Æ÷ÇÔÇϰí, È£¾à¿°±â¼ºÀ» ³ªÅ¸³½´Ù.
  • bone marrow cell
    °ñ¼ö ¼¼Æ÷
  • bristle cell
    °­¸ð ¼¼Æ÷, ¸ð¼¼Æ÷
  • calcigerous cell
    ¼®È¸È­ ¼¼Æ÷
  • cameloid cell
    Ÿ¿øÇü ÀûÇ÷±¸
  • cancer cell
    ¾Ï ¼¼Æ÷
    Á¤»óÀÎ Á¶Á÷ ¼¼Æ÷°¡ ¾î¶² ¿øÀÎÀ¸·Î ¹«Á¦ÇÑ Áõ½ÄÇÏ¿© ±× »ýüÀÇ »ýȰÇö»óÀ̳ª ÁÖÀ§ÀÇ Á¶Á÷ »óÅ µî¿¡ °ü°è¾øÀÌ ±Þ¼ÓÇÑ ¹ßÀ°À» °è¼ÓÇÏ¿© ¸¶Ä§³»´Â »ý¸íÀ» ²÷°Ô ÇÏ´Â ¾Ç¼ºÀÇ ½Å»ý¹°À̶ó°íµµ º¼ ¼ö ÀÖ´Â ¼¼Æ÷. ¼¼Æ÷ÇÐÀûÀ¸·Î º¸¸é ±× ¸ð¾çÀ̳ª Å©±â°¡ Á¤»ó ¼¼Æ÷¿¡ ºñÇÏ¿© ´Ù¼Ò º¯È­µÇ¾î ÀÖ´Ù. Áï, ÇÙÀº ¿°»öü°¡ ¸¹°í, ÇÙÀÇ ¿øÇüÁú¿¡ ´ëÇÑ ºñ°¡ Å©¸ç, ÇÙ¼Òü¸¦ °¡Áö°í, ÀÚÁÖ ÇÙ ºÐ¿­»óÀ» ³ªÅ¸³½´Ù. À̰ÍÀ» ÀÌÇü¼ºÀ̶ó°í ÇÑ´Ù. ÀÌÇü¼ºÀÌ °­ÇÑ °ÍÀÌ ¾Ï ¼¼Æ÷ÀÇ Æ¯Â¡ÀÌ´Ù. À̰ÍÀ» ÀÌ¿ëÇÑ °ÍÀÌ ¼¼Æ÷ÁøÀ̸ç, À§¾Ï µî ¸ðµç ¾ÏÀÇ Á¶±â Áø´Ü¿¡ Å« ¿ªÇÒÀ» Çϰí ÀÖ´Ù. Á¤»ó ¼¼Æ÷°¡ ¾î¶»°Ô ÇØ¼­ ¾Ï ¼¼Æ÷·Î º¯Çϴ°¡´Â ºÒ¸í·áÇÑ Á¡ÀÌ ¸¹Áö¸¸, È÷¸£È¿ÀÇ Àڱؼ³Àº À¯¸íÇÏ´Ù. À̰ÍÀº È­ÇÐÀû, ±â°èÀû, ¹°¸®Àû µîÀÇ ¸¸¼º ÀÚ±ØÀÌ ÀÛ¿ëÇÏ´Â °÷¿¡ ¾ÏÀÌ ¹ß»ýÇÑ´Ù´Â ¼³ÀÌ´Ù. ¹ÙÀÌ·¯½º¿ÍÀÇ °ü°èµµ ±Ù³â¿¡ ÁÖ¸ñÀ» ²ø¾î, F.P. ¶ó¿ì½ºÀÇ ´ßÀÇ À°Á¾ ¹ÙÀÌ·¯½º³ª R.E. ¼îÇÁÀÇ Åä³¢ÀÇ À¯µÎÁ¾ ¹ÙÀÌ·¯½º´Â À¯¸íÇÏÁö¸¸, Àΰ£ÀÇ ¾Ï°ú È®½ÇÇÏ°Ô °ü°è¸¦ °®´Â ¹ÙÀÌ·¯½º´Â ¾ÆÁ÷ ¹ß°ßÇÏÁö ¸øÇϰí ÀÖ´Ù. ¾Ï ¼¼Æ÷°¡ Á¤»ó ¼¼Æ÷¿Í ´Ù¸¥ Á¡Àº ÀÚÀ²ÀûÀ¸·Î Áõ½ÄÇϰí ÁÖÀ§ÀÇ Á¶Á÷À» ÆÄ±«ÇÏ¿© ħÀ±¼ºÀ¸·Î ¹ßÀ°ÇÏ´Â °Í, ¾Ï ¼¼Æ÷°¡ À¯¸®µÇ¾î ¸²ÇÁÇ༺, Ç÷Ç༺À¸·Î ¿ø°Ý Àå±â¿¡ ÀüÀÌÇÏ´Â °Í, ÆÄÁ¾À̶ó ÇÏ¿© º¹°­³»³ª Èä°­³»ÀÇ Àå±âÀÇ ¾Ï¿¡¼­´Â ¾Ï ¼¼Æ÷°¡ À帷¿¡ µµ´ÞÇÏ¸é º¹¸·À̳ª È丷¿¡ ºÎÂøÇÏ¿© ¹ßÀ°À» °è¼ÓÇÏ´Â °Í µîÀÌ´Ù. ÀÌ·± Ư¼º ¶§¹®¿¡ ¾ÏÀÇ Ä¡·á°¡ º¹ÀâÇØÁö°í Àç¹ßµÇ±â ½±´Ù. µû¶ó¼­ ¾ÏÀ» °íÄ¡·Á¸é ¾Ï ¼¼Æ÷°¡ ÀÌ·± Ư¼ºÀ» ÃæºÐÈ÷ ¹ßÈÖÇÏÁö ¸øÇÏ´Â Á¶±â¿¡ ¹ß°ß, Ä¡·áÇØ¾ß ÇÑ´Ù.
  • capsule cell
    ÇǸ· ¼¼Æ÷, À§¼º ¼¼Æ÷
  • caterpillar cell
    ¸ðÃæ ¼¼Æ÷
  • caveolated cell
    ¼ÒÆ÷¿ò ¼¼Æ÷
    ÈçÈ÷ º¼ ¼ö ÀÖ´Â °ÍÀº ¾Æ´ÏÁö¸¸, ¼ÒÀå, ´ëÀå, À§ µîÀÇ ¿ò°ú À¶¸ð¿¡¼­ º¼ ¼ö ÀÖ´Ù. ²À´ë±âº¸´Ù ¹Ù´Ú ºÎºÐÀÌ ³ÐÀ¸¸ç ²À´ë±â¿¡´Â ¹Ì¼¼ À¶¸ð°¡ Àִµ¥ ±× ¼Ó¿¡´Â ¼¼»ç ´Ù¹ßÀÌ ÇÔÀ¯µÇ¾î ÀÖÀ¸¸ç, ÀÌµé ¼¼»ç ´Ù¹ß »çÀÌ¿¡ ¼¼Æ÷¸·ÀÌ ÇÔÀÔµÈ ¼Ò¿òµéÀÌ ÀÖ´Ù.
  • cell
    ¼¼Æ÷, ¹úÁý, ºÀ¼Ò
    1. »ýü Á¶Á÷ÀÇ ±âº» ´ÜÀ§. Çö¹Ì°æÀ¸·Î °üÂûÀÌ °¡´ÉÇÑ À¯±âü¸¦ ±¸¼ºÇÏ´Â ´Ù¾çÇÑ ¿øÇüÁú µ¢¾î¸® Áß ÇÑ °¡Áö. °¢ ¼¼Æ÷´Â ¼¼Æ÷¸·, ¿øÇüÁú, ÇÙ, ´Ù¾çÇÑ ºÀÀÔü¸¦ °¡Áö°í ÀÖ´Ù. °¢ ¼¼Æ÷ Á¾·ù´Â °¢°¢ÀÇ ´ë»ç ¿ä±¸, ÀÛ¿ë, Åõ°úµµ, ´Ù¸¥ ¼¼Æ÷·Î ºÐÈ­ÇÏ´Â ´É·Â, Àç»ý»ê¼º°ú ¼ö¸íÀ» °¡Áø »ì¾Æ ÀÖ´Â ´ÜÀ§ÀÌ´Ù. 2. »ý¹°ÀÇ ¸öÀ» ±¸¼ºÇÏ´Â ÃÖ¼ÒÀÇ ´ÜÀ§. ¸¹Àº »ý¹°Àº ´Ù¼öÀÇ ¼¼Æ÷·Î ÀÌ·ç¾îÁ® Àֱ⠶§¹®¿¡ ´Ù¼¼Æ÷ »ý¹°À̶ó°í ÇÏÁö¸¸, ¾î¶² Á¾¿¡¼­´Â ±× ÀÚü°¡ ÇϳªÀÇ ¼¼Æ÷·Î µÇ¾î Àֱ⠶§¹®¿¡ ´Ü¼¼Æ÷»ý¹°À̶ó ÇÑ´Ù. ¼¼±Õ, ±ÔÁ¶, ¹Ý´Þ¸», Ŭ·Î·¼¶ó¿Í °°Àº °£´ÜÇÑ Á¶·ù, ¾Æ¸Þ¹Ù, ¤½Å¹ú·¹¿Í °°Àº ¿ø»ýµ¿¹° µîÀº ´Ü¼¼Æ÷»ý¹°ÀÌ´Ù. º¸Åë µ¿¹°ÀÇ ³­ÀÚ´Â ¹ß»ý Ãʱ⿡´Â ´Ü¼¼Æ÷ÀÌÁö¸¸, °ð ºÐ¿­ÇÏ¿© ´Ù¼¼Æ÷·Î µÈ´Ù. ´«À¸·Î º¸ÀÌ´Â °Í¿¡´Â ¹ß»ý ÃʱâÀÇ µ¿¹°ÀÇ ³­ÀÚ, ½Å°æ¼¼Æ÷
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 10
hepatitis B surface antigen <virology> A serologic marker on the surface of the hepatitis B virus. The body will normally produce antibodies to hepatitis B surface antigen as part of the normal immune response to infection. It is the presence of antibodies to the hepatitis B surface antigen that are detected in a positive hepatitis B blood test.
(27 Sep 1997)
prostate-specific antigen <tumour marker> A simple blood test used to detect prostate cancer in men. The test measures a specific antigen normally secreted by the prostate. If cancer is developing, the prostate secretes greater amounts of prostate-specific antigen. This test is recommended for men with an enlarged prostate and an increased risk of prostate cancer.
It is an enzyme that is produced by epithelial cells of both benign and malignant prostate tissue. It is an important marker for the diagnosis of prostate cancer.
It is a single chain 31 kilodalton glycoprotein with 240 amino acid residues and 4 carbohydrate side chains that is a kallikrein protease.
It is found in normal seminal fluid and produced by the prostatic epithelial cells.
Elevated levels in blood serum are associated with prostatic enlargement and prostatic adenocarcinoma, and this allows early detection of cancer in many cases. In about 70% of cases, the rise is due to a cancerous condition.
No large scale clinical studies have been completed to assess the impact of testing on survival from prostate cancer, and the medical and economic value of testing remain uncertain.
Acronym: PSA
Registry number: EC 3.4.21.77
(22 Sep 2002)
heterogeneic antigen An antigen or antigenic determinant which is found in different tissues in more than one species.
(05 Mar 2000)
heterogenetic antigen An antigen which is possessed by a variety of different phylogenetically unrelated species; e.g., the various organ-or tissue-specific antigen's, the alpha-and beta-crystalline protein of the lens of the eye, and Forssman antigen.
Synonym: heterophil antigen.
(05 Mar 2000)
heterogenic enterobacterial antigen Cross reacting antigen (epitope), a common antigen that occurs in 2 or more different molecules/organisms.
Synonym: heterogenic enterobacterial antigen.
(05 Mar 2000)
heterophil antigen An antigen which is possessed by a variety of different phylogenetically unrelated species; e.g., the various organ-or tissue-specific antigen's, the alpha-and beta-crystalline protein of the lens of the eye, and Forssman antigen.
Synonym: heterophil antigen.
(05 Mar 2000)
heterophile antigen An antigen or antigenic determinant which is found in different tissues in more than one species.
(05 Mar 2000)
Xg antigen xg blood group
histocompatibility antigen <immunology> A set of plasmalemmal glycoproteins on the surface of all nucleated cells that are crucial for T-cell recognition of antigens. Particularly the HLA system in humans and the H2 system in mice. They are the major antigens responsible for tissue recognition. For this reason, they are of prime importance in determining compatible organ donors for a specific transplantation procedure. Each person has unique HLA antigens. Some HLA antigens have been identified to be correlated with the presence of certain autoimmune diseases. One of these is the HLA-B27 site. Approximately 85% of patients with ankylosing spondylitis and Reiter's syndrome will have the HLA-B27 antigen present on the leukocytes.
There are two classes of histocompatibility antigens:
1. Class I, histocompatibility antigens composed of two glycosylated subunits, a heavy chain of 44 kD and beta2 microglobulin (12 kD). The heavy chain may be coded by K, D or L genes of mouse H2 and A, B or C genes of human HLA complex. Class I antigens are important in T-cell killing and are recognised in conjunction with the foreign cell surface antigens MHC restriction).
2. Class II antigens, heterodimeric histocompatibility antigens composed of alpha (32 kD) and beta (28 kD) chains. Found mostly on B lymphocytes, macrophages and accessory cells. The response of T helper cells requires that the foreign antigen is presented in conjunction with the appropriate Class II antigens. (Murine H2 Ia antigens and human HLA DR antigens are Class II).
(14 Oct 1997)
HLA-a1 antigen <immunology> Human histocompatibility (HLA) surface antigen encoded by the a locus on chromosome 6. Individuals bearing this allele are more susceptible to hodgkin's disease. HLA-a1 is in linkage disequilibrium with HLA-b8 and HLA-dr3.
(12 Dec 1998)
HLA-a2 antigen <immunology> Human histocompatibility (HLA) surface antigen encoded by the a locus on chromosome 6. The HLA-a2 antigen is associated with recognition of the influenza a virus.
(12 Dec 1998)
HLA-a3 antigen <immunology> Human histocompatibility (HLA) surface antigen encoded by the a locus on chromosome 6. The allele occurs with increased frequency in individuals with idiopathic haemochromatosis. HLA-a3 is in linkage disequilibrium with HLA-b7 and HLA-dr2.
(12 Dec 1998)
HLA-b27 antigen <immunology> Human histocompatibility (HLA) surface antigen encoded by the b locus on chromosome 6. It is strongly associated with acute anterior uveitis, ankylosing spondylitis, and reiter's disease.
Increased frequency of antigen in: ankylosing spondylitis (90%), Reiter syndrome (90%), enteropathic arthritis (75%), psoriatic arthritis (60%) normal frequency: white: 8%, black: 4%
(12 Dec 1998)
HLA-b35 antigen <immunology> Human histocompatibility (HLA) surface antigen encoded by the b locus on chromosome 6. It is weakly associated with a number of diseases.
(12 Dec 1998)
HLA-b7 antigen <immunology> Human histocompatibility (HLA) surface antigen encoded by the b locus on chromosome 6. There is a weak association between the presence of the HLA-b7 antigen and the diseases of narcolepsy and idiopathic haemochromatosis. HLA-b7 is in linkage disequilibrium with HLA-a3 and HLA-dr2.
(12 Dec 1998)
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 10
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 10
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 10
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 10
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 10
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 10
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 10
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 10
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 10
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 10
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 10
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 10
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 10
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 10
  • ¿µ¹®
    ÇѱÛ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 10
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 10
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 10
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 10
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 10
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 10
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 10
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 10
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 10
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 10
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 10
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 10
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 10
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 10
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 10
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 10
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 10
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 10
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 10
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 10
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 10
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 10
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 10
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 10
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 10
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 10
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 10
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 10
  • ¿µ¹®
    ÇѱÛ
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 10
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 10
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 10
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 10
ÅëÇÕ°Ë»ö ¿Ï·á